In the landmark Iressa Pan-ASia Study (IPASS) study, gefitinib (Iressa), a mutated epidermal growth factor receptor (EGFR) inhibitor, demonstrated superiority to carboplatin and paclitaxel in treating patients with lung cancer in East Asia [6]. Here, EGFR is linked to lung carcinoma.